GOLGA8DP: A Potential Drug Target and Biomarker (G100132979)

Target Name: GOLGA8DP

NCBI ID: G100132979

GOLGA8DP

Other Name(s): golgin A8 family member D, pseudogene | Golgin A8 family member D, pseudogene | GOLGA8D

GOLGA8DP: A Potential Drug Target and Biomarker

Golgi80 (also known as GLO80) is a protein that is expressed in most tissues and is involved in various cellular processes. One of its functions is to transport and present proteins to the endoplasmic reticulum (ER), which is the body's main organ for protein synthesis and degradation. GOLGA8DP is a subunit of the Golgi80 complex and is composed of two long chains of polypeptides.

Golgi80 is a protein that is known to play a crucial role in the regulation of protein trafficking in eukaryotic cells. In addition to its role in protein presentation, Golgi80 is also involved in the formation of the endoplasmic reticulum vesicle, which is the structure in which proteins are processed and then transported to the ER.

GOLGA8DP has been shown to be a potential drug target in various diseases. For example, studies have shown that inhibiting Golgi80 can reduce the amount of protein produced in cancer cells, which can lead to a decrease in cell proliferation. In addition, Golgi80 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

One of the reasons why Golgi80 is considered a potential drug target is its location in the endoplasmic reticulum, which is a drug-hard to reach target. However, researchers are still exploring new ways to target Golgi80 and its role in disease.

Another potential benefit of Golgi80 as a drug target is its role in the regulation of inflammation. Studies have shown that Golgi80 is involved in the production of pro-inflammatory cytokines, which contribute to the development of inflammatory diseases. By targeting Golgi80, researchers hope to reduce the production of pro-inflammatory cytokines and improve the effectiveness of treatments for inflammatory diseases.

In addition to its potential drug-targeting properties, Golgi80 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that Golgi80 levels are elevated in various diseases, such as cancer, neurodegenerative diseases, and autoimmune diseases. By using Golgi80 as a biomarker, researchers can monitor the effectiveness of treatments and make early diagnoses of disease.

Golgi80 has also been shown to play a role in the regulation of cellular processes that are important for human health. For example, Golgi80 is involved in the production and degradation of many proteins that are important for maintaining cellular structure and function. In addition, Golgi80 is also involved in the regulation of the endoplasmic reticulum, which is responsible for the delivery of proteins to the body's cells.

In conclusion, Golgi80 is a protein that has the potential to be a drug target and biomarker for various diseases. As more research is conducted on Golgi80, it is likely that its role in these processes will become better understood, and new treatments and diagnoses will be developed.

Protein Name: Golgin A8 Family Member D, Pseudogene

The "GOLGA8DP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA8DP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets